Alteryx (AYX) PT Lowered to $66 at Needham & Company

Alteryx (AYX) PT Lowered to $60 at Loop Capital

Loop Capital analyst Yun Kim lowered the price target on Alteryx (NYSE: AYX) to $60.00 (from $80.00) while maintaining a Hold rating.... More

Alteryx (AYX) PT Lowered to $87 at Rosenblatt

Rosenblatt analyst Blair Abernethy lowered the price target on Alteryx (NYSE: AYX) to $87.00 (from $100.00) while maintaining a Buy rating following strong results with the could product offering expanding.

The analyst commented, "Tuesday after market close, Alteryx reported Q4 results that were above our... More

William Blair Reiterates Outperform Rating on Alteryx (AYX), Sees Stock as Materially Undervalued and as a Buying Opportunity

William Blair analyst Kamil Mielczarek reiterated an Outperform rating and {REMOVEPT} price target on Alteryx (NYSE: AYX)

The analyst quotes: "

Alteryxs December quarter results came in slightly above preannounced estimates. Guidance for the March quarter and calendar 2022 was broadly strong. ARR is expected to grow 27% at the midpoint to $810 million and revenue growth is expected to accelerate... More

Alteryx (AYX) PT Lowered to $127 at JMP Securities

JMP Securities analyst Patrick Walravens lowered the price target on Alteryx (NYSE: AYX) to $127.00 (from $159.00) while maintaining a Market Outperform rating.... More

Alteryx (AYX) PT Raised to $70 at JPMorgan

JPMorgan analyst Mark Murphy raised the price target on Alteryx (NYSE: AYX) to $70.00 (from $65.00) while maintaining a Neutral rating.... More

After-Hours Stock Movers 02/15: (HOOK) (UPST) (AYX) Higher; (RBLX) (TOST) (VIAC) Lower (more...)

After-Hours Stock Movers:

HOOKIPA Pharma Inc. (NASDAQ: HOOK) 53.7% HIGHER; entered into an amended and restated collaboration and license agreement with Gilead to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV).

Upstart Holdings (NASDAQ: UPST) 21.9% HIGHER; reported Q4 EPS of $0.89, $0.38 better than the analyst estimate of $0.51. Revenue for the quarter came in at $304.8 million versus the... More

Alteryx (AYX) Tops Q4 EPS by 12c

Alteryx (NYSE: AYX) reported Q4 EPS of $0.17, $0.12 better than the analyst estimate of $0.05. Revenue for the quarter came in at $173.8 million versus the consensus estimate of $165.79 million.

GUIDANCE:

Alteryx sees FY2022 EPS of ($0.68)-($0.58), versus the consensus of ($0.08). Alteryx sees... More